Saddadi Fereshteh, Najafi Iraj, Hakemi Monir Sadat, Falaknazi Kianoosh, Attari Fatemeh, Bahar Babak
Nephrology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Kidney Dis. 2010 Jan;4(1):20-6.
Bone marrow transplantation (BMT) is a major modality for malignant and hematologic disorders. This procedure is associated with a high morbidity and mortality such as acute kidney injury (AKI). Many factors, such as therapeutic agents, irradiation, and graft versus host disease (GVHD) can cause AKI. Bone marrow transplantation conditioning therapy in Iran is based on drugs such as busulfan and cyclophosphamide and without irradiation therapy. The aim of this study was to evaluate the frequency, risk factors, and mortality of AKI among patients who underwent BMT.
Acute kidney injury was defined as doubling serum creatinine from baseline at any time during the first 180 days posttransplant. The risk of AKI in relation to non-total-body-irradiation-based conditioning regimen, type of graft (allograft and autograft), comorbidities, GVHD, drug toxicity, and veno-occlusive disease were examined in 375 patients with BMT.
One hundred and forty-two patients (37.6%) developed AKI at a median of 18 days after transplant. A higher frequency of AKI was observed in patients who received cyclosporine A (40%), patients with allograft BMT (42.1%), and those who developed gastrointestinal GVHD (47.3%) .The remainder AKI cases were associated with amphotericin B, veno-occlusive disease, and hemolytic-uremic syndrome.
The frequency of AKI in our patients with BMT remained high. Cyclosporine A and amphotericin B and the presence of GVHD and veno-occlusive disease increased the risk of AKI within the first 180 days after BMT.
骨髓移植(BMT)是治疗恶性和血液系统疾病的主要方式。该手术伴随着高发病率和死亡率,如急性肾损伤(AKI)。许多因素,如治疗药物、放疗和移植物抗宿主病(GVHD)都可导致AKI。伊朗的骨髓移植预处理疗法基于白消安和环磷酰胺等药物,且不进行放疗。本研究的目的是评估接受BMT患者中AKI的发生率、危险因素和死亡率。
急性肾损伤定义为移植后180天内任何时间血清肌酐较基线水平翻倍。在375例接受BMT的患者中,研究了与非全身照射预处理方案、移植物类型(同种异体移植和自体移植)、合并症、GVHD、药物毒性和静脉闭塞性疾病相关的AKI风险。
142例患者(37.6%)在移植后中位18天发生AKI。接受环孢素A的患者(40%)、同种异体BMT患者(42.1%)以及发生胃肠道GVHD的患者(47.3%)中观察到较高的AKI发生率。其余AKI病例与两性霉素B、静脉闭塞性疾病和溶血尿毒综合征有关。
我们的BMT患者中AKI的发生率仍然很高。环孢素A、两性霉素B以及GVHD和静脉闭塞性疾病的存在增加了BMT后180天内AKI的风险。